Ubavitinib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR; CD117), with potential antineoplastic activity. Upon oral administration, ubavitinib specifically targets, binds to and inhibits specific mutant forms of PDGFRa and c-Kit. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants. PDGFRa and c-Kit, protein tyrosine kinases, are upregulated or mutated in various tumor cell types; they play key roles in the regulation of cellular proliferation and resistance to chemotherapy.

**Synonyms:** - AZD 3229 - AZD-3229 - AZD3229 - N-(4-((5-Fluoro-7-(2-Methoxyethoxy)Quinazolin-4-Yl)Amino)Phenyl)-2-(4-(Propan-2-Yl)-1h-(1,2,3)Triazol-1-Yl)Acetamide - NB 003 Free Base - NB-003 Free Base - NB003 Free Base - UBAVITINIB